Repatha Indications/Uses

Established atherosclerotic cardiovascular disease: Evolocumab (Repatha) is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
For study results with respect to effects on LDL-C, cardiovascular events and populations studied see Pharmacology: Pharmacodynamics under Actions.
Hyperlipidaemia (Including Heterozygous Familial Hypercholesterolaemia [HeFH]): Evolocumab (Repatha) is indicated in adults with hyperlipidaemia, alone or in combination with other lipid-lowering therapies, as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C).
Paediatric Patients with Heterozygous Familial Hypercholesterolaemia: Evolocumab (Repatha) is indicated in paediatric patients aged 10 years and over with HeFH as an adjunct to diet, alone or in combination with other lipid-lowering therapy, to reduce LDL-C.
Homozygous familial hypercholesterolaemia: Evolocumab (Repatha) is indicated in adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.